Adaptor proteins that control integrin signaling in immune and cardiovascular cells
Molecular Mechanisms Underlying Adaptor-Mediated Integrin Signaling in a Species-Specific Manner
['FUNDING_OTHER'] · RESEARCH INST OF FOX CHASE CAN CTR · NIH-11245699
The team is working to understand how adaptor proteins control integrin signals and to develop new drugs that could help people with autoimmune or cardiovascular conditions linked to abnormal cell adhesion.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST OF FOX CHASE CAN CTR (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11245699 on ClinicalTrials.gov |
What this research studies
From a patient's view, the researchers are studying proteins that help cells stick and move, because those signals can go wrong in autoimmune and blood-vessel diseases. They will examine different versions of these adaptor proteins and chemical modifications to see how each affects integrin behavior in cells. The lab will test potential inhibitor molecules in cell models and in preclinical systems to find ones that can safely block harmful signaling. Over time the best candidates could move toward safety testing and early human studies.
Who could benefit from this research
Good fit: People with autoimmune diseases, thrombotic disorders, or cardiovascular conditions thought to involve abnormal integrin activity would be most relevant to this research.
Not a fit: Patients whose illnesses are unrelated to integrin or adaptor-protein pathways are unlikely to benefit from these specific findings in the near term.
Why it matters
Potential benefit: If successful, this work could lead to a new class of medicines that better control immune cell activation or reduce harmful clotting in cardiovascular disease.
How similar studies have performed: Existing drugs target integrins on the cell surface, but directly blocking intracellular adaptor proteins is a newer and less-tested approach with limited clinical precedent.
Where this research is happening
PHILADELPHIA, UNITED STATES
- RESEARCH INST OF FOX CHASE CAN CTR — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WU, JINHUA — RESEARCH INST OF FOX CHASE CAN CTR
- Study coordinator: WU, JINHUA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, Cardiovascular Diseases